You are here

Home » Library » Topic Index » Antiretroviral Therapy » Pharmacologic Topics

Pharmacologic Topics

Archive Resources: 2

Online and Self-Paced Learning

Pocket Guides

Articles: 11

  • Long-Acting Injectable ART: Cabotegravir + Rilpivirine

    Susa Coffey's picture

    April 25, 2019

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    At CROI 2019, investigators presented 48-week results from the Phase 3 international multisite ATLAS and FLAIR studies of long-acting 2-drug injectable therapy. The study regimen consisted of the integrase inhibitor cabotegravir (CAB) plus the NNRTI rilpivirine (RPV), both given every 4 weeks as...

  • Doravirine--New NNRTI Approved by FDA

    Susa Coffey's picture

    October 10, 2018

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    The U.S. Food and Drug Administration has approved the NNRTI doravirine for use in initial HIV therapy. FDA approval was based on 48-week results of 2 Phase III studies in treatment-naive persons that showed doravirine + 2 NRTIs resulted in similar rates of viral suppression at 48 weeks as...

  • Tenofovir Alafenamide (TAF) and Darunavir/Cobicistat in Pregnant Women

    Jennifer Cocohoba's picture

    September 25, 2018

    Two pharmacokinetic studies from AIDS 2018 help elucidate the disposition of tenofovir alafenamide (TAF) and cobicistat-boosted darunavir during pregnancy.

    The IMPAACT P1026s study examined plasma concentrations of TAF with and without cobicistat in 43 pregnant women. For women taking...

  • Possible Safety Issue with Dolutegravir during Pregnancy: Reports of Neural Tube Defects

    Susa Coffey's picture

    May 23, 2018

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    On May 18, 2018, the U.S. Food and Drug Administration and the World Health Organization announced that cases of neural tube defects have been reported in babies of women with HIV who were on treatment with dolutegravir at the time of conception and during early pregnancy. The...

  • Rifampin Drug-Drug Interactions with Newer Antiretrovirals (TAF, Bictegravir, Dolutegravir)

    Jennifer Cocohoba's picture

    April 11, 2018

    Treatment of tuberculosis (TB) in HIV-infected persons remains challenging, in part because of drug interactions between rifampin and some ARVs that may compromise antiretroviral therapy (ART). Three studies presented at CROI provide clinicians with additional guidance on how to manage certain...

  • Doravirine in Initial Therapy: DRIVE-AHEAD Study

    Susa Coffey's picture

    October 3, 2017

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    Doravirine (DOR) is an investigational NNRTI that currently is being developed in a coformulation with TDF and FTC. A Phase 3 comparison of DOR + 2 NRTIs (87% of study subjects were given TDF/FTC) and DRV/r + 2 NRTIs in initial therapy was presented at CROI earlier this year (DRIVE-FORWARD); the...

  • On the Way: The First Protease Inhibitor-Based Single-Tablet Regimen

    Jennifer Cocohoba's picture

    September 28, 2017

    The EMERALD Study is a Phase 3 randomized (2:1), open-label, noninferiority study examining the strategy of switching patients with suppressed HIV RNA on a regimen consisting of a boosted protease inhibitor plus tenofovir disoproxil fumarate (TDF)/emtricitabine to an investigational single-...

  • Bictegravir in Initial Therapy

    Susa Coffey's picture

    September 28, 2017

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    Bictegravir (BIC) is an investigational integrase inhibitor that is being studied as part of a coformulation with tenofovir alafenamide (TAF) and emtricitabine (FTC). Two Phase 3 trials comparing a single-tablet regimen of BIC/TAF/FTC (50/25/200 mg) with regimens containing dolutegravir (DTG)...

  • Efavirenz, Dolutegravir, and Darunavir: Pharmacokinetics during Pregnancy

    Jennifer Cocohoba's picture

    April 12, 2016

    Three studies presented at the 2016 Conference on Retroviruses and Opportunistic Infections (CROI) explored the pharmacokinetics of antiretrovirals administered during pregnancy. These studies support the use of standard-dose efavirenz, once-daily dolutegravir, and BID ritonavir-boosted...

  • Switching from TDF/FTC to TAF/FTC

    Susa Coffey's picture

    March 18, 2016

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    Researchers at the 2016 Conference on Retroviruses and Opportunistic Infections presented results from a randomized double-blind, double-dummy switch study of TAF/FTC. Over 660 patients with virologic suppression on TDF/FTC-containing 3-drug regimens were either switched to TAF/FTC (200/10 mg...

  • Tissue Levels of TAF: Too Low for PrEP?

    Susa Coffey's picture

    March 17, 2016

    • Susa Coffey, MD, AETC National Coordinating Resource Center, UCSF Center for HIV Information

    There was a pharmacokinetic study presented at the Conference on Retroviruses and Opportunistic Infections in Boston in February. It evaluated concentrations of tenofovir (TFV) and TFV-diphosphate (DP) in genital and rectal tissue. Also in anogenital fluid samples after administration of oral...